Weill Cornell Medicine investigators have developed a method to expand human endothelial cells from just a small biopsy sample, potentially generating enough cells to rebuild damaged blood vessels or nourish organs for transplantation. Published in Nature Cardiovascular Research, the study describes how treating adult endothelial cells with a small molecule awakens dormant cells, allowing them to divide repeatedly without aging, mutating, or losing function.

Endothelial cells line blood vessels and regulate circulation, inflammation, and tissue healing, but efforts to grow them at scale have long been hampered by their tendency to stop dividing after a few cycles. According to senior author Shahin Rafii, “Our technology allows clinical labs to use a small biopsy taken in a doctor’s office and ultimately produce a trillion or more functional endothelial cells, without acquiring any aberrant features.”

The team found that small molecules inhibiting the aryl hydrocarbon (AH) receptor could rouse adult endothelial cells and enable them to multiply exponentially. This receptor normally keeps many adult endothelial cells in a quiescent state by regulating gene expression. By blocking the pathway, the researchers achieved up to a 100-fold increase in cell yield, producing as many as two trillion stable, functional cells from adult tissue samples, including fat biopsies. These expanded cells retained genomic stability, normal gene profiles, and the ability to form vascular structures. “It’s like a fountain of youth—the cells don’t age and don’t become cancerous, which is critical for clinical therapy,” Rafii said.

Search Antibodies
Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.

Probing deeper, first authors Yang Lin and Fuqiang Geng discovered that the inhibitors did not simply suppress the AH receptor’s typical activity but redirected it to influence cellular metabolism in new ways. Dr. Lin noted, “We thought that if we knocked down AH receptor gene expression genetically, we should have more proliferation even without the inhibitor, but we found that was not true.” The compounds instead shifted how the receptor interacted with proteins associated with oxidation and metabolism. They reduced harmful reactive oxygen species and promoted alternative energy pathways, supporting continued cell renewal and preserving genomic integrity. The process also elevated polyamine production, a key factor in normal cell growth and survival.

This approach could provide the cellular foundation needed to engineer patient-specific vascular grafts, improve tissue regeneration, and develop organ replacements at clinical scale.